

March 31, 2022 PeptiGrowth Inc.

# PeptiGrowth Inc. is Launching A Novel Synthetic TrkB agonist peptide (BDNF alternative)


PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel TrkB agonist peptide (BDNF alternative) which has the equivalent functions to recombinant BDNF; Brain Derived Neurotropic Factor. We will be marketing this product from the beginning of April, 2022.

## Development of Synthetic Peptide Growth Factors by PeptiGrowth

Conventional growth factors and cytokines used in the manufacturing of regenerative medicine and cell therapy products are facing various challenges such as lot-to-lot quality variation, potential contamination with biological impurities, low stability, and high cost. PeptiGrowth has been working on the development of a series of synthetic peptides that have the same functions as conventional growth factors and cytokines, and that can address and solve all these challenges. Its peptides are completely chemically synthesized and animal component-free.

### About TrkB agonist peptide (BDNF alternative) [Product code: PG-003]

Signal activation equivalent to recombinant BDNF



We performed a functional comparison test between our TrkB agonist peptide and commercially available recombinant BDNF. From the results, TrkB agonist peptide showed the property which promotes the phosphorylation of TrkB receptor and the expression of NFAT-responsive reporter gene at the same level



per molecule compared with recombinant BDNF. The molecular weight of TrkB agonist peptide is approximately 5.1 kDa, which is approximately 2.5 times smaller than that of recombinant BDNF. Our TrkB agonist peptide is expected to be used as a neurotrophic factor to grow, induce and maintain neurons derived from neural progenitors. The product can be applied to several protocols in nerve regenerative medicine and cell therapy recently developed for several types of neurons.

Product Overview

| TrkB agonist peptide (BDNF alternative) |
|---|
| PG-003                                  |
| Lyophilized                             |
| -20 °C or less                          |
| ≥95% by HPLC                            |
| 5151.66                                 |
| 10 µg (volume per a glass vial)         |
|   |

\*This product can be provided Animal Component Free (ACF) certificate.

\*This product is for testing and research use only (RUO).

\*There is a possibility that the specification would be changed.

## Purchase Our Product

If you would like to purchase our products, please contact us at the information below. For customers who would like to purchase GMP compliant products as well as the above PG products in bulk scale, please contact us using the information provided below.

## Development of other peptides from PeptiGrowth

PeptiGrowth was established in April 2020 as a joint venture between Mitsubishi Corporation and PeptiDream Inc. with the missions to address various challenges that regenerative medicine and cell therapy industry is facing and to contribute to its growth. Following HGF Alternative Peptide and TGF $\beta$ 1 inhibitor and BDNF alternative peptide, PeptiGrowth is planning to launch the next product by the end of September 2022. Details will be updated on its website upon release.

## Contact for US Market

Mitsubishi International Food Ingredients, Inc. Jes Kuruvilla, PhD Tel : + 1 (201) 681-1268 E-mail: FineChem@mitsubishiingredients.com **Contact for Other Market** PeptiGrowth Inc, Yosuke Ushimaru Tel : + 81-70-4503-1497 E-mail: yosuke.ushimaru@peptigrowth.com